Advice

Advice

NICE is unable to make a recommendation about the use in the NHS of eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received from Novartis for the technology.

  • National Institute for Health and Care Excellence (NICE)